Update on Adjustable Trans-Obturator Male System (ATOMS) for Male Incontinence after Prostate Cancer Surgery.

adjustable trans-obturator male system artificial urinary sphincter effectiveness post-prostatectomy incontinence prostate cancer safety

Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
12 04 2023
Historique:
received: 10 02 2023
revised: 03 04 2023
accepted: 10 04 2023
medline: 17 5 2023
pubmed: 15 5 2023
entrez: 15 5 2023
Statut: epublish

Résumé

(1) Background: The adjustable trans-obturator male system (ATOMS) is a surgical device developed to treat post-prostatectomy incontinence (PPI) after prostate cancer treatment. We review the current literature on this anti-incontinence device with the intention of assessing the effectiveness, safety and duration of the silicone-covered scrotal port (SSP) ATOMS, the only generation of the device that is currently available. (2) Material and Methods: Non-systematic literature review is performed. Forty-eight full-text articles are assessed for eligibility. Case reports, expert opinions or commentaries without specific data reported (

Identifiants

pubmed: 37185429
pii: curroncol30040316
doi: 10.3390/curroncol30040316
pmc: PMC10136884
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

4153-4165

Références

Adv Ther. 2017 May;34(5):1173-1183
pubmed: 28405960
Prostate Cancer Prostatic Dis. 2022 Jun 21;:
pubmed: 35729329
World J Urol. 2017 Jan;35(1):145-151
pubmed: 27156092
Neurourol Urodyn. 2019 Feb;38(2):710-718
pubmed: 30575997
Neurourol Urodyn. 2020 Aug;39(6):1746-1752
pubmed: 32496612
Adv Urol. 2012;2012:835290
pubmed: 22536227
Int Braz J Urol. 2021 Nov-Dec;47(6):1131-1135
pubmed: 33861057
Minerva Urol Nefrol. 2020 Dec;72(6):770-777
pubmed: 31692302
BJU Int. 2015 Feb;115(2):300-7
pubmed: 24731208
Int J Impot Res. 2021 Sep;33(6):577-582
pubmed: 32499613
Front Surg. 2022 Feb 14;9:825239
pubmed: 35237650
Can Urol Assoc J. 2022 May;16(5):E256-E260
pubmed: 34941490
World J Urol. 2019 Aug;37(8):1679-1686
pubmed: 30377812
Adv Ther. 2021 Jan;38(1):678-690
pubmed: 33230712
J Clin Med. 2022 Aug 19;11(16):
pubmed: 36013121
Urology. 2016 Apr;90:189-94
pubmed: 26773347
Int Braz J Urol. 2021 Mar-Apr;47(2):423-425
pubmed: 33284546
PLoS One. 2019 Dec 2;14(12):e0225762
pubmed: 31790490
Urol Int. 2018;101(1):106-113
pubmed: 29953998
Actas Urol Esp (Engl Ed). 2018 Sep;42(7):473-482
pubmed: 29642999
World J Urol. 2019 Oct;37(10):2189-2197
pubmed: 30649591
J Urol. 2012 Mar;187(3):956-61
pubmed: 22264469
J Pers Med. 2022 Jan 12;12(1):
pubmed: 35055409
Health Technol Assess. 2022 Aug;26(36):1-152
pubmed: 35972773
World J Urol. 2020 Jul;38(7):1795-1803
pubmed: 31542824
Urology. 2021 Nov;157:120-127
pubmed: 34425151
Int Urol Nephrol. 2016 Oct;48(10):1571-6
pubmed: 27417131
Transl Androl Urol. 2017 Jul;6(Suppl 2):S112-S121
pubmed: 28791230
Eur Urol. 2013 Apr;63(4):681-9
pubmed: 23219375
Neurourol Urodyn. 2021 Jun;40(5):1089-1097
pubmed: 33851426
J Urol. 2019 Nov;202(5):1022-1028
pubmed: 31251715
Urology. 2021 Feb;148:280-286
pubmed: 33181122
Front Surg. 2021 Apr 09;8:647656
pubmed: 33898508
J Basic Clin Physiol Pharmacol. 2022 Apr 07;34(1):49-54
pubmed: 35390245
Neurourol Urodyn. 2020 Aug;39(6):1737-1745
pubmed: 32496606
Transl Androl Urol. 2022 Aug;11(8):1200-1209
pubmed: 36092846
J Clin Med. 2021 Dec 24;11(1):
pubmed: 35011821
Adv Ther. 2019 Feb;36(2):426-441
pubmed: 30560525
J Clin Med. 2023 Mar 15;12(6):
pubmed: 36983297
Urology. 2015 Sep;86(3):602-7
pubmed: 26135815
Neurourol Urodyn. 2021 Mar;40(3):897-909
pubmed: 33645867
Neurourol Urodyn. 2022 Feb;41(2):609-615
pubmed: 34969148
World J Urol. 2021 Apr;39(4):1083-1092
pubmed: 32529450
BJU Int. 2017 May;119(5):785-792
pubmed: 27868328
BJU Int. 2006 Jun;97(6):1234-41
pubmed: 16686718
Neurourol Urodyn. 2018 Apr;37(4):1458-1466
pubmed: 29315765
Eur Urol Focus. 2016 Aug;2(3):245-259
pubmed: 28723370
BJU Int. 2005 Jun;95(9):1364-6
pubmed: 15892832
Actas Urol Esp (Engl Ed). 2018 May;42(4):267-272
pubmed: 29174630

Auteurs

Carlos Téllez (C)

Clinical Department, Faculty of Biomedical Sciences, Universidad Europea, 28805 Madrid, Spain.
Urology Department, Hospital Universitario de Getafe, 28805 Madrid, Spain.

Juliusz Szczesniewski (J)

Clinical Department, Faculty of Biomedical Sciences, Universidad Europea, 28805 Madrid, Spain.
Urology Department, Hospital Universitario de Getafe, 28805 Madrid, Spain.

Miguel Virseda-Chamorro (M)

Urology Department, Hospital Nacional de Parapléjicos, Carretera de la Peraleda, S/N, 45004 Toledo, Spain.

Ignacio Arance (I)

Clinical Department, Faculty of Biomedical Sciences, Universidad Europea, 28805 Madrid, Spain.
Urology Department, Hospital Universitario de Getafe, 28805 Madrid, Spain.

Javier C Angulo (JC)

Clinical Department, Faculty of Biomedical Sciences, Universidad Europea, 28805 Madrid, Spain.
Urology Department, Hospital Universitario de Getafe, 28805 Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH